M&A

three triple doors opportunity cracked open ajar
Biotech

89bio was left between a Roche and a hard place in buyout talks

Over three years, 89bio signed confidentiality agreements with 14 biopharmas as it advanced its MASH candidate.
Nick Paul Taylor Oct 2, 2025 9:55am
Novo

Novo vs. KBP Chapter 2: 'Anomalous' trial results

Oct 2, 2025 3:00am
puzzle pieces merger and acquisition business concept
Favicon Fierce Pharma

Halozyme buys Elektrofi for up to $900M

Oct 1, 2025 2:36pm
Metallic arrow symbols which are illuminated by blue and magenta lights merge on blue and magenta b

Barinthus enters reverse merger with metabolic disease biotech

Sep 30, 2025 10:39am
increase

Biopharma biobucks decline, while upfront deal payments rise

Sep 24, 2025 11:30am
photo of a pair of binoculars perched on a rock aimed at the rising sun
Favicon Fierce Pharma

New Incyte CEO takes 'fresh look' at business, outlines BD plan

Aug 4, 2025 11:16am